Danish drugmaker Novo Nordisk said Friday it would invest 42 billion kroner ($6 billion) to expand manufacturing facilities in efforts to meet massive demand for its anti-diabetes and anti-obesity treatments. Sales of the Ozempic and Wegovy treatments have made Novo Nordisk the most valuable company in Europe by market capitalisaiton….